Cutler Group’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$55K Sell
9,700
-14,500
-60% -$924K 0.02% 627
2023
Q4
$261K Sell
24,200
-26,900
-53% -$1.36M 0.02% 630
2023
Q3
$31K Buy
51,100
+41,700
+444% +$1.83M ﹤0.01% 1740
2023
Q2
$167K Buy
9,400
+2,300
+32% +$198K 0.02% 696
2023
Q1
$62K Sell
7,100
-52,700
-88% -$3.04M 0.01% 1213
2022
Q4
$258K Buy
59,800
+8,000
+15% +$424K 0.02% 668
2022
Q3
$931K Buy
51,800
+11,300
+28% +$669K 0.06% 325
2022
Q2
$26K Sell
40,500
-14,400
-26% -$657K ﹤0.01% 2449
2022
Q1
$351K Buy
54,900
+48,300
+732% +$2.13M 0.02% 844
2021
Q4
$49K Sell
6,600
-64,600
-91% -$2.54M ﹤0.01% 2408
2021
Q3
$33K Buy
71,200
+56,900
+398% +$3.2M ﹤0.01% 2876
2021
Q2
$205K Buy
14,300
+11,800
+472% +$609K 0.01% 1328
2021
Q1
$6K Buy
2,500
+2,000
+400% +$94.6K ﹤0.01% 4195
2020
Q4
$6K Sell
500
-1,900
-79% -$80.4K ﹤0.01% 3499
2020
Q3
$4K Buy
2,400
+1,000
+71% +$29.9K ﹤0.01% 3601
2020
Q2
$4K Sell
1,400
-800
-36% -$25.7K ﹤0.01% 3406
2020
Q1
$3K Sell
2,200
-14,500
-87% -$515K ﹤0.01% 3278
2019
Q4
$86K Buy
16,700
+14,800
+779% +$410K 0.01% 1279
2019
Q3
$7K Buy
+1,900
New +$52.3K ﹤0.01% 2803

Other funds holding APLS

Cutler Group's APLS Position: Q1 2024 in Review

Cutler Group sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 10,201 shares — an estimated $650K sold.

Cutler Group first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $3.35M in Q3 2021. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Cutler Group reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 10,201 Apellis Pharmaceuticals shares in Q1 2024, an estimated $650K.
  • Cutler Group first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
  • Cutler Group's Apellis Pharmaceuticals position peaked at $3.35M in Q3 2021.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.